Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy
Where
Beijing
Age
18 years and over
People
224
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07014202
No phaseNot yet taking people in China
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC
Where
Fuzhou
Age
18 years and over
People
35
Run by
Fuzhou General Hospital
See details and how to joinNCT07093762
Phase 2Taking people
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
Where
Changsha, Xi'an, Yinchuan
Age
18 years and over
People
27
Run by
Tang-Du Hospital
See details and how to joinNCT06864624
Phase 2Taking people
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Where
Zibo
Age
18 years to 75 years
People
20
Run by
Zibo Municipal Hospital
See details and how to joinNCT07085182
No phaseTaking people
Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLC
Where
Tianjin
Age
65 years to 100 years
People
120
Run by
Kong Fanming
See details and how to joinNCT07086300
Phase 2Not yet taking people in China
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
Where
Beijing, Changsha, Hangzhou, Shanghai, Xi’an
Age
18 years and over
People
164
Run by
Yang Fan, MD
See details and how to joinNCT07086326
Phase 2Taking people
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
80
Run by
Sun Yat-sen University
See details and how to joinNCT07086456
Phase 1/2Taking people
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure
Where
Baoding, Baotou, Beijing, Dalian, Neimeng, Tianjin
Age
18 years and over
People
42
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07087223
Phase 3Taking people
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
Where
Guangzhou
Age
18 years to 75 years
People
497
Run by
Sun Yat-sen University
See details and how to joinNCT06734702
No phaseTaking people
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
Where
Beijing, Changsha, Hefei
Age
18 years to 75 years
People
240
Run by
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
See details and how to joinNCT06926140
Phase 2Not yet taking people in China
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
Where
Beijing
Age
18 years and over
People
56
Run by
Zhijie Wang
See details and how to joinNCT07083375
Phase 2Taking people
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Where
Chengdu
Age
18 years to 75 years
People
40
Run by
Sichuan University
See details and how to joinNCT06951464
Phase 3Taking people
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
Where
Chongqing, Guangzhou, Lanzhou
Age
18 years to 75 years
People
311
Run by
Sun Yat-sen University
See details and how to joinNCT07052669
Phase 2Taking people
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Where
Shenzhen
Age
18 years to 75 years
People
105
Run by
Fudan University
See details and how to joinNCT04136535
Phase 2Taking people
A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases
Where
Chongqing
Age
18 years to 75 years
People
427
Run by
Xinqiao Hospital of Chongqing
See details and how to joinNCT06947694
No phaseTaking people
Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases
Where
Hangzhou
Age
18 years and over
People
100
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07008287
No phaseTaking people
Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
Where
Chengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou
Age
18 years and over
People
110
Run by
Jiayuan Sun
See details and how to joinNCT06572540
No phaseTaking people
Transbronchial MWA for Pulmonary Tumors
Where
Shanghai
Age
18 years and over
People
15
Run by
Shanghai Chest Hospital
See details and how to joinNCT06969014
Phase 2Taking people
Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Where
Jinan
Age
18 years and over
People
30
Run by
Shandong Public Health Clinical Center
See details and how to joinNCT06709859
No phaseTaking people
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
Where
Shanghai
Age
45 years to 80 years
People
38
Run by
Shanghai Chest Hospital of Shanghai Jiao Tong University
See details and how to joinNCT07070011
Phase 2Taking people
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Where
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Wuhan, Xiangyang, Yibin, Yiyang, Yueyang, Yunnan, Zhengzhou
Age
18 years to 75 years
People
80
Run by
RemeGen Co., Ltd.
See details and how to joinNCT06962865
Phase 2Taking people
Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.
Where
Jinan
Age
18 years to 75 years
People
36
Run by
Hua Zhang
See details and how to joinNCT06617936
No phaseTaking people
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
Where
Chongqing
Age
18 years to 75 years
People
20
Run by
Xinqiao Hospital of Chongqing
See details and how to joinNCT05486650
No phaseTaking people
Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
Where
Chongqing
Age
18 years to 75 years
People
40
Run by
Xinqiao Hospital of Chongqing
See details and how to joinNCT05754203
Phase 1Taking people
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Where
Guangzhou
Age
18 years and over
People
101
Run by
Guangzhou JOYO Pharma Co., Ltd
See details and how to joinNCT06128148